![]() Prior to his graduate studies, he spent 5 years as a research scientist in reputable research organizations namely GVK Bio, India ( (2006-2007) and Dr. He holds American patent while work with Johns Hopkins-School of Medicine, USA and this molecule in phase II clinical trials for treating cancer. ![]() Lett., ACS Chem Bio, J Comb Chem and Bioconugate Chem) and Elsevier (Tetrahedron Letters) journals which are featured many times in Chem. He authored with more than 28 international peer-reviewed high impact publications such as PNAS, Wily ( Angew Chemie), RSC ( Chem Comm and Org Biomol Chem), most of American Chemical Society journals ( Journal of American Chemical Society, Org. His graduate research work is focused on “ Synthesis of bioactive amino acid building blocks and their applications towards the peptides and glycopeptides.” His have total 16 years of academic and industry experience with major multinationals companies & academic institutions and have worked with many collaborative professors around the globe. Kalyan Kumar Pasunooti pursued his PhD degree from Nanyang Technological University (NTU) ( Singapore (2007 – 2011) in the field of Medicinal, Peptide & Protein chemistry. Novel Tetrazole-Containing Analogues of Itraconazole as Potent Antiangiogenic Agents with Reduced Cytochrome P450 3A4 Inhibitionĭr. These results suggest that 15n is a promising angiogenesis inhibitor that can be used in combination with most other known anticancer drugs. Similar to itraconazole, 15n induced Niemann-Pick C phenotype (NPC phenotype) and blocked AMPK/mechanistic target of rapamycin signaling. Among these analogues, 15n with tetrazole in place of 1,2,4-triazole exhibited optimal inhibition of human umbilical vein endothelial cell proliferation with an IC 50 of 73 nM without a significant effect on CYP3A4 (EC 50 > 20 μM). In an effort to eliminate the CYP3A4 inhibition while retaining its antiangiogenic activity, we designed and synthesized a series of derivatives in which the 1,2,4-triazole ring is replaced with various azoles and nonazoles. The wider use of itraconazole in the treatment of cancer, however, has been limited by its potent inhibition of the drug metabolizing enzyme cytochrome P450 3A4 (CYP3A4). Itraconazole has been found to possess potent antiangiogenic activity, exhibiting promising antitumor activity in several human clinical studies. ChinaĮthyl 2-(4-(benzyloxy)phenyl)-4-oxo-1,4-dihydroquinoline-3-carboxylate (3u) White solid, m.p. He is an active member of Initiative for Research and Innovation in Science (IRIS) supported by Intel’s Education Initiative to organize National Science Fair and popularize science in India.ĪArtermisinin Research Center and Institute of Chinese Meteria Medica, Academy of Chinese Medical Sciences, Beijing, P. His research areas include: (i) design and applications of microreactors, (ii) design of multiphase reactors, (iii) experimental and computational fluid dynamics, and (iv) nonlinear dynamics of coupled systems. He has been awarded with the Max-Planck-Visiting Fellowship from the Max-Planck-Society, Munich for 2008-2011. At NCL he is driving a research program on the design of microreactors and exploring their applications for continuous syntheses including of nanoparticles. In 2004 he worked at the Max Planck Institute-Magdeburg (Germany) as a Alexander von Humboldt Research Fellow. in chemical engineering (2003) all from the University Dept. Kulkarni is a Scientist in the Chemical Engineering Division at the National Chemical Laboratory.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |